ReviewPharmaceutics2023
Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Polymersome-based nanomedicine for combined cancer therapy.Drug delivery · 2026Review
- Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026Review
- Hitting the bullseye: PSMA-targeted small molecule drug conjugate for prostate cancer treatment.RSC advances · 2026Article
- Nanocarrier-based delivery of Pt(IV) compounds for chemoimmunotherapy and theranostics: Advances, challenges, and prospects.Acta pharmaceutica Sinica. B · 2026Review
- Guiding off-target nanomedicine repurposing in spleen for cancer immunotherapy.Journal of nanobiotechnology · 2026Article
- Barrier-Oriented Design of Next-Generation Polymeric Nanocarriers for Targeted Drug Delivery.Molecules (Basel, Switzerland) · 2026Review
- The role of targeted exosomes in improving drug delivery in breast cancer: challenges and prospects.Molecular biology reports · 2026Review
- Coordination chemistry-enabled drug delivery systems: metal-ligand platforms for controlled release and targeted therapeutics.Journal of nanobiotechnology · 2026Review
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- Transferosomes as Advanced Nanocarriers for Enhanced Drug Delivery in Skin Cancer Therapy: A Comprehensive Review.Applied biochemistry and biotechnology · 2026Review
- Advancing brain immunotherapy through functional nanomaterials.Drug delivery and translational research · 2026Review
- Exploiting the role of milk extracellular vesicles: a comprehensive analysis on isolation methods, characterization, surface modifications, and their therapeutic applications.Journal of nanobiotechnology · 2026Review
- Structural, Swelling, and In Vitro Digestion Behavior of DEGDA-Crosslinked Semi-IPN Dextran/Inulin Hydrogels.Gels (Basel, Switzerland) · 2026Article
- Equip your vehicle for the right terrain: Using features of local pathology to guide engineering of targeted drug delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Advances of Peptide-Drug Conjugates in the Treatment of Digestive System Tumors.Drug design, development and therapy · 2026Review
- Peptide-Based Nanocarriers for Targeted Drug Delivery: Recent Advances, Strategies, and Therapeutic Frontiers.International journal of nanomedicine · 2026Review
- Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance.Frontiers in oncology · 2026Review
- Unraveling the Role of Tumor-infiltrating Immune Cells in Modulating Cancer Drug Resistance.Anti-cancer agents in medicinal chemistry · 2026Review
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Targeted drug delivery is a precise and effective strategy in oncotherapy that can accurately deliver drugs to tumor cells or tissues to enhance their therapeutic effect and, meanwhile, weaken their undesirable side effects on normal cells or tissues. In this research field, a large number of researchers have achieved significant breakthroughs and advances in oncotherapy. Typically, nanocarriers as a promising drug delivery strategy can effectively deliver drugs to the tumor site through enhanced permeability and retention (EPR) effect-mediated passive targeting and various types of receptor-mediated active targeting, respectively. Herein, we review recent targeted drug delivery strategies and technologies for enhancing oncotherapy. In addition, we also review two mainstream drug delivery strategies, passive and active targeting, based on various nanocarriers for enhancing tumor therapy. Meanwhile, a comparison and combination of passive and active targeting are also carried out. Furthermore, we discuss the associated challenges of passive and active targeted drug delivery strategies and the prospects for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.